Found: 160
Select item for more details and to access through your institution.
Coexistent cutaneous myeloid sarcoma in a patient with invasive papillary carcinoma of thyroid - A rare presentation.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Electrochemical Investigations of the Anticancer Drug Idarubicin Using Multiwalled Carbon Nanotubes Modified Glassy Carbon and Pyrolytic Graphite Electrodes.
- Published in:
- Electroanalysis, 2013, v. 25, n. 6, p. 1473, doi. 10.1002/elan.201300048
- By:
- Publication type:
- Article
Preparation, characterization and evaluation of <sup>186</sup>Re-idarubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2016, v. 59, n. 2, p. 72, doi. 10.1002/jlcr.3368
- By:
- Publication type:
- Article
Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Addition of All-Trans Retinoic Acid to the combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older Patients with AML Does Not Improve The Outcome in Those with NPM1 Mutations The addition of All-Trans Retinoic Acid to Chemotherpay may not Improve The Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
- Published in:
- Frontiers in Oncology, 2013, v. 3, p. 1, doi. 10.3389/fonc.2013.00218
- By:
- Publication type:
- Article
Optimized Loading of Idarubicin in CalliSpheres ® Drug-Eluting Beads and Characterization of Release Profiles and Morphological Properties.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 6, p. 799, doi. 10.3390/pharmaceutics13060799
- By:
- Publication type:
- Article
Acute myeloid leukemia with misleading cytology.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Solitary central nervous system relapse in acute promyelocytic leukemia.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Fortuitous discovery of an NPM1 mutation in a myelodysplastic syndrome.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Chronic myelomonocytic leukaemia: leukaemia cutis predicts disease progression.
- Published in:
- 2019
- By:
- Publication type:
- Case Study
Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 1, p. 12, doi. 10.3390/ijms18010012
- By:
- Publication type:
- Article
Mucormycosis in a Patient with Acute Myeloid Leukemia Successfully Treated with Liposomal Amphotericin B Associated with Deferasirox and Hyperbaric Oxygen.
- Published in:
- Mycopathologia, 2013, v. 175, n. 3/4, p. 295, doi. 10.1007/s11046-013-9629-0
- By:
- Publication type:
- Article
In vitro evaluation of the reductive carbonyl idarubicin metabolism to evaluate inhibitors of the formation of cardiotoxic idarubicinol via carbonyl and aldo–keto reductases.
- Published in:
- Archives of Toxicology, 2024, v. 98, n. 3, p. 807, doi. 10.1007/s00204-023-03661-7
- By:
- Publication type:
- Article
Usefulness of a Medication Instruction Sheet for Patients Receiving Cytarabine and Idarubicin Induction Therapy for Acute Myeloid Leukemia.
- Published in:
- In Vivo, 2023, v. 37, n. 2, p. 924, doi. 10.21873/invivo.13164
- By:
- Publication type:
- Article
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin.
- Published in:
- Pharmacogenomics Journal, 2013, v. 13, n. 4, p. 335, doi. 10.1038/tpj.2012.13
- By:
- Publication type:
- Article
Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
- Published in:
- Pediatrics International, 2017, v. 59, n. 10, p. 1046, doi. 10.1111/ped.13378
- By:
- Publication type:
- Article
Miliaria crystallina induced by idarubicin and all‐trans‐retinoic acid: Two case reports.
- Published in:
- Australasian Journal of Dermatology, 2021, v. 62, n. 3, p. e408, doi. 10.1111/ajd.13641
- By:
- Publication type:
- Article
A Case of Acute Myeloid Leukemia with a Previously Unreported Translocation (14; 15) (q32; q13).
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Breast cancer.
- Published in:
- 2000
- Publication type:
- Abstract
Designing Biodegradable Wafers Based on Poly(L-lactide-co-glycolide) and Poly(glycolide-co-ε-caprolactone) for the Prolonged and Local Release of Idarubicin for the Therapy of Glioblastoma Multiforme.
- Published in:
- Pharmaceutical Research, 2020, v. 37, n. 5, p. 1, doi. 10.1007/s11095-020-02810-2
- By:
- Publication type:
- Article
Phase I Study to Determine the Maximal Tolerated Dose and Dose-Limiting Toxicities of Orally Administered Idarubicin in Dogs with Lymphoma.
- Published in:
- Journal of Veterinary Internal Medicine, 2012, v. 26, n. 3, p. 608, doi. 10.1111/j.1939-1676.2012.00896.x
- By:
- Publication type:
- Article
4-Demethoxydaunorubicin (Idarubicin) in refractory or relapsed acute leukemias. A pilot study.
- Published in:
- 1985
- By:
- Publication type:
- journal article
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 3, p. 535, doi. 10.1111/bjh.18193
- By:
- Publication type:
- Article
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 3, p. e169, doi. 10.1111/bjh.16804
- By:
- Publication type:
- Article
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17‐10 CIARA trial).
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 2, p. 235, doi. 10.1111/bjh.15546
- By:
- Publication type:
- Article
Haemophagocytosis by neoplastic cells in aleukaemic variant of mast cell leukaemia.
- Published in:
- British Journal of Haematology, 2016, v. 174, n. 4, p. 501, doi. 10.1111/bjh.14178
- By:
- Publication type:
- Article
Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R- IDARAM chemotherapy.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 4, p. 545, doi. 10.1111/bjh.13867
- By:
- Publication type:
- Article
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 5, p. 646, doi. 10.1111/bjh.13189
- By:
- Publication type:
- Article
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 2, p. 233, doi. 10.1111/bjh.13035
- By:
- Publication type:
- Article
Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 3, p. 375, doi. 10.1111/bjh.12905
- By:
- Publication type:
- Article
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Hypercalcemia associated with interaction between all trans retinoic acid and fluconazole in an acute promyelocytic leukemia and acquired hypoparathyroidism case.
- Published in:
- Journal of Oncology Pharmacy Practice, 2024, v. 30, n. 3, p. 605, doi. 10.1177/10781552231216050
- By:
- Publication type:
- Article
Papilledema and idiopathic intracranial hypertension due to the possible potentiation of ATRA by posaconazole in a case of acute promyelocytic leukemia.
- Published in:
- Journal of Oncology Pharmacy Practice, 2022, v. 28, n. 6, p. 1474, doi. 10.1177/10781552221076756
- By:
- Publication type:
- Article
Two successful deliveries of healthy children by a young woman diagnosed and treated during induction and relapsed therapy for acute promyelocytic leukemia.
- Published in:
- Journal of Oncology Pharmacy Practice, 2020, v. 26, n. 8, p. 2034, doi. 10.1177/1078155220915764
- By:
- Publication type:
- Article
Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report.
- Published in:
- Journal of Oncology Pharmacy Practice, 2020, v. 26, n. 2, p. 507, doi. 10.1177/1078155219861422
- By:
- Publication type:
- Article
FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
- Published in:
- Journal of Oncology Pharmacy Practice, 2019, v. 25, n. 8, p. 1831, doi. 10.1177/1078155218817816
- By:
- Publication type:
- Article
Fournier's gangrene: a surgical emergency.
- Published in:
- Infection, 2016, v. 44, n. 1, p. 143, doi. 10.1007/s15010-015-0816-4
- By:
- Publication type:
- Article
Dismal outcome of therapy-related myeloid neoplasm associated with complex aberrant karyotypes and monosomal karyotype: a case report.
- Published in:
- Malaysian Journal of Pathology, 2016, v. 38, n. 3, p. 315
- By:
- Publication type:
- Article
Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study.
- Published in:
- 2001
- By:
- Publication type:
- Letter
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies.
- Published in:
- 2000
- By:
- Publication type:
- journal article
Interferon may reduce minimal residual disease of acute promyelocytic leukemia.
- Published in:
- 2000
- By:
- Publication type:
- Case Study
3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.
- Published in:
- 2000
- By:
- Publication type:
- Letter
Idarubicin DNA intercalation is reduced by MRP1 and not Pgp.
- Published in:
- 1999
- By:
- Publication type:
- journal article
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
- Published in:
- 1999
- By:
- Publication type:
- journal article
Response from Estey to X Thomas et al.
- Published in:
- 1998
- By:
- Publication type:
- commentary
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia.
- Published in:
- 1998
- By:
- Publication type:
- journal article
A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia.
- Published in:
- 1998
- By:
- Publication type:
- journal article